Ampersand Capital Partners to acquire Vibalogics

30 May 2019

USA-based private equity firm Ampersand Capital Partners announced plans to acquire Vibalogics GmbH, a German contract development and manufacturing organization (CDMO) focused on complex live biological products.

Ampersand’s growth investment will be used to expand Vibalogics’ capabilities to meet rapidly growing industry demand for the development and manufacturing of complex viral products. Financial terms of the transaction were not disclosed.

Vibalogics offers process development, manufacturing and fill & finish of products for biopharmaceutical companies involved in the development of oncolytic viral therapies, gene therapies, and vaccines. With a specific focus on viruses, live bacteria, and aseptic processing, the company’s 50 employees work in full compliance with international GMP standards in a BSL-2 classified state of the art, 27,000 sq ft (2,500 m2) facility in Cuxhaven, Germany.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK